No!
RT @boback: Guess all the bioplausibility stuff didn't work out too well. https://t.co/0PzblT2wzE https://t.co/zHOuZWjitd
Guess all the bioplausibility stuff didn't work out too well. https://t.co/0PzblT2wzE https://t.co/zHOuZWjitd
@J_Brooksbank Very interested! PARAGON-HF was unique in that its primary endpoint included both first and recurrent heart failure hospitalizations. Something that should have improved power - https://t.co/FgY9KdhIJs https://t.co/8zwphqVP7E
RT @Cardio_delaGuia: Sacubitril/Valsartan en insuficiencia cardiaca con FEVI conservada... ¿puede ser útil? https://t.co/0HGbuUkJs0 https:/…
RT @Cardio_delaGuia: Sacubitril/Valsartan en insuficiencia cardiaca con FEVI conservada... ¿puede ser útil? https://t.co/0HGbuUkJs0 https:/…
RT @JACCJournals: Design and rationale of the PARAGON trial: Earn CME/MOC for this article! #JACCHF https://t.co/9ldFgHmAhm https://t.co/ye…
RT @Cardio_delaGuia: Sacubitril/Valsartan en insuficiencia cardiaca con FEVI conservada... ¿puede ser útil? https://t.co/0HGbuUkJs0 https:/…
Angiotensin Receptor Neprilysin Inhibition in Heart Failure With Preserved Ejection Fraction https://t.co/dbjkFaaNhW
RT @Cardio_delaGuia: Sacubitril/Valsartan en insuficiencia cardiaca con FEVI conservada... ¿puede ser útil? https://t.co/0HGbuUkJs0 https:/…
RT @Cardio_delaGuia: Sacubitril/Valsartan en insuficiencia cardiaca con FEVI conservada... ¿puede ser útil? https://t.co/0HGbuUkJs0 https:/…
RT @Cardio_delaGuia: Sacubitril/Valsartan en insuficiencia cardiaca con FEVI conservada... ¿puede ser útil? https://t.co/0HGbuUkJs0 https:/…
RT @Cardio_delaGuia: Sacubitril/Valsartan en insuficiencia cardiaca con FEVI conservada... ¿puede ser útil? https://t.co/0HGbuUkJs0 https:/…
RT @Cardio_delaGuia: Sacubitril/Valsartan en insuficiencia cardiaca con FEVI conservada... ¿puede ser útil? https://t.co/0HGbuUkJs0 https:/…
RT @Cardio_delaGuia: Sacubitril/Valsartan en insuficiencia cardiaca con FEVI conservada... ¿puede ser útil? https://t.co/0HGbuUkJs0 https:/…
Sacubitril/Valsartan en insuficiencia cardiaca con FEVI conservada... ¿puede ser útil? https://t.co/0HGbuUkJs0 https://t.co/nSdNt3jGEi
RT @accpcardprn: Will sacubitril/valsartan be helpful in heart failure with preserved EF? PARAGON-HF trialists aim to find out: https://t.c…
RT @accpcardprn: Will sacubitril/valsartan be helpful in heart failure with preserved EF? PARAGON-HF trialists aim to find out: https://t.c…
RT @accpcardprn: Will sacubitril/valsartan be helpful in heart failure with preserved EF? PARAGON-HF trialists aim to find out: https://t.c…
RT @accpcardprn: Will sacubitril/valsartan be helpful in heart failure with preserved EF? PARAGON-HF trialists aim to find out: https://t.c…
RT @accpcardprn: Will sacubitril/valsartan be helpful in heart failure with preserved EF? PARAGON-HF trialists aim to find out: https://t.c…
RT @accpcardprn: Will sacubitril/valsartan be helpful in heart failure with preserved EF? PARAGON-HF trialists aim to find out: https://t.c…
RT @accpcardprn: Will sacubitril/valsartan be helpful in heart failure with preserved EF? PARAGON-HF trialists aim to find out: https://t.c…
Will sacubitril/valsartan be helpful in heart failure with preserved EF? PARAGON-HF trialists aim to find out: https://t.co/k28UUDySx8
RT @JACCJournals: Design and rationale of the PARAGON trial: Sacubitril/valsartan in HFpEF. #JACCHF @BrighamWomens https://t.co/kLpFWNjJ3u…
RT @JACCJournals: Design and rationale of the PARAGON trial: Sacubitril/valsartan in HFpEF. #JACCHF @BrighamWomens https://t.co/kLpFWNjJ3u…
RT @JACCJournals: Design and rationale of the PARAGON trial: Earn CME/MOC for this article! #JACCHF https://t.co/9ldFgHmAhm https://t.co/ye…
RT @JACCJournals: Design and rationale of the PARAGON trial: Earn CME/MOC for this article! #JACCHF https://t.co/9ldFgHmAhm https://t.co/ye…
RT @JACCJournals: Design and rationale of the PARAGON trial: Earn CME/MOC for this article! #JACCHF https://t.co/9ldFgHmAhm https://t.co/ye…
RT @JACCJournals: Design and rationale of the PARAGON trial: Sacubitril/valsartan in HFpEF. #JACCHF @BrighamWomens https://t.co/kLpFWNjJ3u…
RT @JACCJournals: Design and rationale of the PARAGON trial: Earn CME/MOC for this article! #JACCHF https://t.co/9ldFgHmAhm https://t.co/ye…
RT @JACCJournals: Design and rationale of the PARAGON trial: Sacubitril/valsartan in HFpEF. #JACCHF @BrighamWomens https://t.co/kLpFWNjJ3u…
Definitely looking forward to the outcomes data! https://t.co/w2K1oUy8it
RT @JACCJournals: Design and rationale of the PARAGON trial: Sacubitril/valsartan in HFpEF. #JACCHF @BrighamWomens https://t.co/kLpFWNjJ3u…
RT @JACCJournals: Design and rationale of the PARAGON trial: Sacubitril/valsartan in HFpEF. #JACCHF @BrighamWomens https://t.co/kLpFWNjJ3u…
RT @JACCJournals: Design and rationale of the PARAGON trial: Sacubitril/valsartan in HFpEF. #JACCHF @BrighamWomens https://t.co/kLpFWNjJ3u…
RT @JACCJournals: Design and rationale of the PARAGON trial: Sacubitril/valsartan in HFpEF. #JACCHF @BrighamWomens https://t.co/kLpFWNjJ3u…
RT @JACCJournals: Design and rationale of the PARAGON trial: Earn CME/MOC for this article! #JACCHF https://t.co/9ldFgHmAhm https://t.co/ye…
RT @JACCJournals: Design and rationale of the PARAGON trial: Earn CME/MOC for this article! #JACCHF https://t.co/9ldFgHmAhm https://t.co/ye…
PARAGON wants to find 4800 #HFpEF patients. Ambitious. https://t.co/V7SyO7uPvx
RT @JACCJournals: Design and rationale of the PARAGON trial: Sacubitril/valsartan in HFpEF. #JACCHF @BrighamWomens https://t.co/kLpFWNjJ3u…
RT @JACCJournals: Design and rationale of the PARAGON trial: Sacubitril/valsartan in HFpEF. #JACCHF @BrighamWomens https://t.co/kLpFWNjJ3u…
RT @JACCJournals: Design and rationale of the PARAGON trial: Sacubitril/valsartan in HFpEF. #JACCHF @BrighamWomens https://t.co/kLpFWNjJ3u…
RT @JACCJournals: Design and rationale of the PARAGON trial: Sacubitril/valsartan in HFpEF. #JACCHF @BrighamWomens https://t.co/kLpFWNjJ3u…
RT @JACCJournals: Design and rationale of the PARAGON trial: Sacubitril/valsartan in HFpEF. #JACCHF @BrighamWomens https://t.co/kLpFWNjJ3u…
RT @JACCJournals: Design and rationale of the PARAGON trial: Sacubitril/valsartan in HFpEF. #JACCHF @BrighamWomens https://t.co/kLpFWNjJ3u…
RT @JACCJournals: Design and rationale of the PARAGON trial: Earn CME/MOC for this article! #JACCHF https://t.co/9ldFgHmAhm https://t.co/ye…
RT @JACCJournals: Design and rationale of the PARAGON trial: Sacubitril/valsartan in HFpEF. #JACCHF @BrighamWomens https://t.co/kLpFWNjJ3u…
RT @JACCJournals: Design and rationale of the PARAGON trial: Sacubitril/valsartan in HFpEF. #JACCHF @BrighamWomens https://t.co/kLpFWNjJ3u…
RT @JACCJournals: Design and rationale of the PARAGON trial: Sacubitril/valsartan in HFpEF. #JACCHF @BrighamWomens https://t.co/kLpFWNjJ3u…
RT @JACCJournals: Design and rationale of the PARAGON trial: Earn CME/MOC for this article! #JACCHF https://t.co/9ldFgHmAhm https://t.co/ye…
RT @JACCJournals: Design and rationale of the PARAGON trial: Sacubitril/valsartan in HFpEF. #JACCHF @BrighamWomens https://t.co/kLpFWNjJ3u…
RT @JACCJournals: Design and rationale of the PARAGON trial: Sacubitril/valsartan in HFpEF. #JACCHF @BrighamWomens https://t.co/kLpFWNjJ3u…
RT @JACCJournals: Design and rationale of the PARAGON trial: Sacubitril/valsartan in HFpEF. #JACCHF @BrighamWomens https://t.co/kLpFWNjJ3u…
RT @JACCJournals: Design and rationale of the PARAGON trial: Earn CME/MOC for this article! #JACCHF https://t.co/9ldFgHmAhm https://t.co/ye…
RT @JACCJournals: Design and rationale of the PARAGON trial: Earn CME/MOC for this article! #JACCHF https://t.co/9ldFgHmAhm https://t.co/ye…
RT @JACCJournals: Design and rationale of the PARAGON trial: Sacubitril/valsartan in HFpEF. #JACCHF @BrighamWomens https://t.co/kLpFWNjJ3u…
RT @JACCJournals: Design and rationale of the PARAGON trial: Earn CME/MOC for this article! #JACCHF https://t.co/9ldFgHmAhm https://t.co/ye…
RT @JACCJournals: Design and rationale of the PARAGON trial: Sacubitril/valsartan in HFpEF. #JACCHF @BrighamWomens https://t.co/kLpFWNjJ3u…
RT @JACCJournals: Design and rationale of the PARAGON trial: Earn CME/MOC for this article! #JACCHF https://t.co/9ldFgHmAhm https://t.co/ye…
RT @JACCJournals: Design and rationale of the PARAGON trial: Sacubitril/valsartan in HFpEF. #JACCHF @BrighamWomens https://t.co/kLpFWNjJ3u…
RT @JACCJournals: Design and rationale of the PARAGON trial: Earn CME/MOC for this article! #JACCHF https://t.co/9ldFgHmAhm https://t.co/ye…
Design and rationale of the PARAGON trial: Earn CME/MOC for this article! #JACCHF https://t.co/9ldFgHmAhm https://t.co/yenMsyV3KY
RT @JACCJournals: Design and rationale of the PARAGON trial: Sacubitril/valsartan in HFpEF. #JACCHF @BrighamWomens https://t.co/kLpFWNjJ3u…
RT @JACCJournals: Design and rationale of the PARAGON trial: Sacubitril/valsartan in HFpEF. #JACCHF @BrighamWomens https://t.co/kLpFWNjJ3u…
RT @JACCJournals: Design and rationale of the PARAGON trial: Sacubitril/valsartan in HFpEF. #JACCHF @BrighamWomens https://t.co/kLpFWNjJ3u…
RT @JACCJournals: Design and rationale of the PARAGON trial: Sacubitril/valsartan in HFpEF. #JACCHF @BrighamWomens https://t.co/kLpFWNjJ3u…
RT @JACCJournals: Design and rationale of the PARAGON trial: Sacubitril/valsartan in HFpEF. #JACCHF @BrighamWomens https://t.co/kLpFWNjJ3u…
RT @JACCJournals: Design and rationale of the PARAGON trial: Sacubitril/valsartan in HFpEF. #JACCHF @BrighamWomens https://t.co/kLpFWNjJ3u…
RT @JACCJournals: Design and rationale of the PARAGON trial: Sacubitril/valsartan in HFpEF. #JACCHF @BrighamWomens https://t.co/kLpFWNjJ3u…
RT @JACCJournals: Design and rationale of the PARAGON trial: Sacubitril/valsartan in HFpEF. #JACCHF @BrighamWomens https://t.co/kLpFWNjJ3u…
RT @JACCJournals: Design and rationale of the PARAGON trial: Sacubitril/valsartan in HFpEF. #JACCHF @BrighamWomens https://t.co/kLpFWNjJ3u…
RT @JACCJournals: Design and rationale of the PARAGON trial: Sacubitril/valsartan in HFpEF. #JACCHF @BrighamWomens https://t.co/kLpFWNjJ3u…
RT @JACCJournals: Design and rationale of the PARAGON trial: Sacubitril/valsartan in HFpEF. #JACCHF @BrighamWomens https://t.co/kLpFWNjJ3u…
RT @JACCJournals: Design and rationale of the PARAGON trial: Sacubitril/valsartan in HFpEF. #JACCHF @BrighamWomens https://t.co/kLpFWNjJ3u…
Design and rationale of the PARAGON trial: Sacubitril/valsartan in HFpEF. #JACCHF @BrighamWomens https://t.co/kLpFWNjJ3u https://t.co/0030wIlw5j
A new review on the PARAGON-HF trial from this year's Lucian Award winner...... https://t.co/QN7fOaydLf
RT @mendez_bailon: Diseño estudio PARANGON: sacubitril-valsartan 97/103mgr/12h comparandose con valsartan 160mgr/12h.@IcaSemes @umipic http…
RT @mendez_bailon: Diseño estudio PARANGON: sacubitril-valsartan 97/103mgr/12h comparandose con valsartan 160mgr/12h.@IcaSemes @umipic http…
RT @mendez_bailon: Diseño estudio PARANGON: sacubitril-valsartan 97/103mgr/12h comparandose con valsartan 160mgr/12h.@IcaSemes @umipic http…
RT @mendez_bailon: Diseño estudio PARANGON: sacubitril-valsartan 97/103mgr/12h comparandose con valsartan 160mgr/12h.@IcaSemes @umipic http…
RT @mendez_bailon: Diseño estudio PARANGON: sacubitril-valsartan 97/103mgr/12h comparandose con valsartan 160mgr/12h.@IcaSemes @umipic http…
RT @mendez_bailon: Diseño estudio PARANGON: sacubitril-valsartan 97/103mgr/12h comparandose con valsartan 160mgr/12h.@IcaSemes @umipic http…
RT @mendez_bailon: Diseño estudio PARANGON: sacubitril-valsartan 97/103mgr/12h comparandose con valsartan 160mgr/12h.@IcaSemes @umipic http…
RT @mendez_bailon: Diseño estudio PARANGON: sacubitril-valsartan 97/103mgr/12h comparandose con valsartan 160mgr/12h.@IcaSemes @umipic http…
RT @mendez_bailon: Diseño estudio PARANGON: sacubitril-valsartan 97/103mgr/12h comparandose con valsartan 160mgr/12h.@IcaSemes @umipic http…
RT @mendez_bailon: Diseño estudio PARANGON: sacubitril-valsartan 97/103mgr/12h comparandose con valsartan 160mgr/12h.@IcaSemes @umipic http…
Diseño estudio PARANGON: sacubitril-valsartan 97/103mgr/12h comparandose con valsartan 160mgr/12h.@IcaSemes @umipic https://t.co/h05YnDBGS2 https://t.co/dhPZwj1DUT
HFpEF is like a carrot dangling in front of pharma that they just can't grab - this unlikely to be different: https://t.co/OzdmAZwbP5
【雑記】ARB・NEP阻害薬 [ARNI] によるHFpEF予後改善作用を、プラセボと比較するRCT "PARAGON-HF" の、デザイン論文出来。 JACC HF https://t.co/U2LOasLV1x 終了予定は再来年3月。